Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Dr. Constantine Tam’s ASH 2019 (Orlando) monologue informs us that the BTK inhibitor zanabrutinib, still in clinical trials, is more specifically targeted than ibrutinib, and therefore better tolerated.
In this 2019 iwCLL interview with Dr. Andy Rawstrom, we learn that he is a clinical scientist who helps with the diagnostics of many UK clinical trials. Dr. Rawstrom explains the value of MRD testing as a strong predictor of the future course of a patient’s CLL.
MRD (minimal or measurable residual disease) is important to understand, not just in clinical trials, but increasingly in guiding real world CLL decisions you may need to make with your doctors. Join Dr. Anthony Mato as he discusses testing and research on MRD and its growing role in CLL management along with Dr. Brian Koffman.
Targeted oral treatment options for CLL and SLL are medications taken by mouth that identify and attack specific cancer cells.
A variety of tests are used to capture images inside the body when chronic lymphocytic leukemia (CLL) and small
lymphocytic lymphoma (SLL) are present. Imaging tests are used to look inside the body to capture pictures that will help the healthcare team visualize what, if any, internal changes might be occurring.
A combination of ibrutinib plus venetoclax is a very effective first-line treatment for CLL, and 90% of patients are progression-free after five years.
Acalabrutinib has a low risk of sudden death and ventricular arrhythmias in chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL) patients.
In real world data, outcomes were equivalent in chronic lymphocytic leukemia patients whether they were first treated with venetoclax or a BTK inhibitor.
Staging in cancer is a process used to determine the extent to which cancer has spread in the body, predict its progression, and guide treatment decisions.
One click to our most popular content.
